Company Encyclopedia
View More
name
B&K CORP-B
02396.HK
B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (“PDGF”) drugs. The company’s pipeline comprised two Core Products including Pro-101-1 for the treatment of deep second-degree thermal burns, which has completed the statistical data analysis for Phase IIb clinical trial, and for the treatment of superficial second-degree thermal burns, which has reached last-patient-out but no statistical data was yet available; and Pro-101-2 for the treatment of diabetic foot ulcers. The company’s products are to address both acute and chronic wounds as well as minor and hard-to-heal wounds including thermal burns, DFUs, fresh wounds, pressure ulcers, radiation ulcers, dry eye syndrome, corneal injury, photodermatitis, alopecia, hemorrhoids, and gastric ulcers.
1.290 T
02396.HKMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking42/54
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-2274.80%E
    • Profit Margin-81321.84%E
    • Gross Margin92.34%A
  • Growth ScoreE
    • Revenue YoY-45.49%E
    • Net Profit YoY-98.90%E
    • Total Assets YoY-29.94%E
    • Net Assets YoY210.39%A
  • Cash ScoreD
    • Cash Flow Margin-0.12%D
    • OCF YoY-45.49%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio21.03%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Four new stocks listed on the Hong Kong stock market this year all fell below their issue prices on the first day of trading

    On December 22, four companies listed on the Hong Kong stock market collectively experienced a decline on their first trading day, namely B&K CORP-B, BENQ HOLDING, NANHUA FUTURES, and IMPRESSION DHP, with first-day drop rates of 29%, 49%, 24%, and 35% respectively. This marks the first occurrence in 2025 of four new stocks collectively declining on their first trading day in the Hong Kong stock market. BENQ HOLDING set a record for the largest first-day drop among new stocks in the Hong Kong market this year. The overall performance of the Hong Kong stock market is under pressure, with an increase in the number of IPOs, average fundamental performance, leading to greater pressure on new stock issuances. The first-day drop rate for Hong Kong IPOs this year is 29%, with nearly half of the new stocks in the fourth quarter experiencing declines

    Wallstreetcn·
    HK
    02581
    +3.60%
    HK
    02396
    -11.78%
    HK
    02691
    +1.10%
    Wallstreetcn·
    HK
    02581
    +3.60%
    HK
    02396
    -11.78%
    HK
    02691
    +1.10%

    Today, four new stocks were listed on the Hong Kong stock market: IMPRESSION DHP, B&K CORP-B, BENQ HOLDING, and NANHUA FUTURES. As of the morning closing, they fell by 25%, 8.5%, 42.3%, and 20.7%, respectively

    Wallstreetcn·
    HK
    02695
    -4.29%
    HK
    02396
    -11.78%
    HK
    02581
    +3.60%
    Wallstreetcn·
    HK
    02695
    -4.29%
    HK
    02396
    -11.78%
    HK
    02581
    +3.60%

    The public offering of B&K CORP-B received 791.95 times subscription, with a 2.5% chance of winning one lot

    B&K CORP-B's public offering was subscribed 791.95 times, with a one-hand winning rate of 2.5%. The international offering recorded a subscription rate of 6.05 times, with a final offer price of 38.2 yuan, raising a net amount of 600 million yuan. The company focuses on wound healing therapies and plans to issue 17,648,800 shares globally, with 10% allocated for the public offering. The shares are expected to be listed on Monday

    AASTOCKS·
    HK
    02396
    -11.78%
    AASTOCKS·
    HK
    02396
    -11.78%

    4 new stocks simultaneously open for subscription. B&K CORP focuses on wound healing drugs. "IMPRESSION DHP" is created by Zhang Yimou

    B&K CORP-B and IMPRESSION DHP are both conducting IPOs simultaneously. B&K CORP-B focuses on wound healing medications and plans to issue approximately 17.6488 million H shares, raising up to HKD 709 million. IMPRESSION DHP is a cultural tourism performance company and plans to issue 36.1 million H shares, raising up to approximately HKD 148 million. Both companies will be listed on December 22

    Stheadline·
    HK
    02396
    -11.78%
    HK
    02695
    -4.29%
    Stheadline·
    HK
    02396
    -11.78%
    HK
    02695
    -4.29%
    © 2025 Longbridge｜Disclaimer